SCHEMBL5982756

SCHEMBL5982756

Nc1ncnc2c1nc(Cl)n2[C@H]1C[C@@H](O)[C@H](CO)O1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ADORA3 P0DMS8 1/20 0.64
▸ ADORA2A P29274 1/20 0.64
▸ AHCY P23526 1/20 0.55
▸ RXFP1 Q9HBX9 2/20 0.54
▸ LMNA P02545 2/20 0.54
▸ TP53 P04637 2/20 0.54
▸ SMN1; SMN2 Q16637 2/20 0.54
▸ PDE4D Q08499 2/20 0.54
▸ PNP P00491 1/20 0.54
▸ HTT P42858 1/20 0.54
▸ PDE3A Q14432 1/20 0.54
▸ HSPA8 P11142 3/20 0.53
▸ HSPA5 P11021 2/20 0.53
▸ HIF1A Q16665 1/20 0.47
▸ HSD17B10 Q99714 1/20 0.47
▸ GAPDH P04406 1/20 0.47
▸ TRPM2 O94759 1/20 0.47
▸ SLC28A2 O43868 1/20 0.46
▸ HBB P68871 1/20 0.46
▸ ADRB1 P08588 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13835023 1.00 ADORA3 (0.64) ADORA3ADORA2AAHCYRXFP1LMNA
SCHEMBL13835026 1.00 ADORA3 (0.64) ADORA3ADORA2AAHCYRXFP1LMNA
SCHEMBL5982752 1.00 ADORA3 (0.64) ADORA3ADORA2AAHCYRXFP1LMNA
SCHEMBL658006 0.88 ADORA3 (0.67) ADORA3ADORA2ARXFP1LMNATP53
SCHEMBL5982491 0.88 ADORA3 (0.51) ADORA3ADORA2ARXFP1LMNATP53
SCHEMBL5982465 0.88 ADORA3 (0.67) ADORA3ADORA2ARXFP1LMNATP53
SCHEMBL5982454 0.88 ADORA3 (0.67) ADORA3ADORA2ARXFP1LMNATP53
SCHEMBL658005 0.88 ADORA3 (0.67) ADORA3ADORA2ARXFP1LMNATP53
SCHEMBL5982489 0.88 ADORA3 (0.51) ADORA3ADORA2ARXFP1LMNATP53
SCHEMBL24420487 0.87 ADORA3 (0.66) ADORA3ADORA2ARXFP1LMNATP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1634888-A2 Synthesis of 2'-deoxy-L-nucleosides Pharmasset Limited (US) 2006-03-15 — — EP disclosed
EP-1600451-A2 Synthesis of 2'-deoxy-l-nucleosides Pharmasset Limited (US) 2005-11-30 — — EP disclosed
EP-1600452-A2 Synthesis of 2'-deoxy-L-nucleosides Pharmasset Limited (US) 2005-11-30 — — EP disclosed
US-20050090660-A1 2'-deoxy-L-nucleosides PHARMASSET, INC. 2005-04-28 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050090660-A1 2'-deoxy-L-nucleosides CCNH, ADAR, NSUN2 ADORA3 14/4885ADORA2A 31/4885AHCY 816/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback